Ashkan Golshani: A Step Closer to Developing a Therapeutic Against Platelet-type von Willebrand Disease
Ashkan Golshani, Professor at Carleton University, Co-founder of Designed Biologics, shared on LinkedIn:
”A step closer to developing a therapeutic against Platelet-type von Willebrand Disease (PT-VWD).
I am extremely proud of my team for developing the first-ever drug candidate against PT-VWD, a rare bleeding disorder (published in Blood Advances).
Using our state-of-the-art artificial intelligence-based drug development platform, my lab has developed a peptide that can reverse the phenotype of the mutant protein causing PT-VWD to its wild-type state.
Many thanks to my wonderful collaborators in this project Dr. Maha Othman and Paolo Gresele and all the members of my laboratory, past and present, especially Thomas Kazmirchuk, who spearheaded this project in my lab.
This work provides additional evidence for the applicability of our proprietary AI technology in developing novel therapeutics and diagnostics, moving us closer to replacing traditional monoclonal antibody development with AI-assisted method.”
Read the full article in Blood Advances.
Article: Developing an AI-Generated Peptide Targeting Platelet-type von Willebrand Disease
Authors: Thomas David Daniel Kazmirchuk, Jiashu Wang, Loredana Bury, Emanuela Falcinelli, Calvin Bradbury-Jost, Anastasiia Koziar, Mustafa Al-gafari, Sarah Takallou, William G Willmore, Frank Dehne, Paolo Gresele, Maha Othman, Ashkan Golshani
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Jun 1, 2026, 18:51Francesco Giurazza: New Publication on Glubran-2 in Acute Bleeding Patients with Coagulopathies
-
Jun 1, 2026, 18:50Donald Arnold is the Recipient of the Roberts Award – ISTH
-
Jun 1, 2026, 18:49Amirreza Jabbaripour Sarmadian: My First Paper as Corresponding Author on Upper Extremity DVT Following COVID-19 Vaccination
-
Jun 1, 2026, 18:49James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
-
Jun 1, 2026, 18:42Debojyoti Chakraborty: Small But Meaningful Steps Toward A Gene Editing Trial For Sickle Cell Disease In India
-
Jun 1, 2026, 17:14Tiffany Gacel: What an Incredible Day With NBCA and The Red Bus Tour at Memorial at Gulfport?
-
Jun 1, 2026, 17:12Marie-Claire Kofi: Poster Highlights the Process of Establishing the Sickle Cell Transitions Policy Lab
-
Jun 1, 2026, 17:00Azusa Nagao: Organizing the Symposium on Women and Bleeding Disorders at JSTH Annual Meeting
-
Jun 1, 2026, 16:57Kuljeet Kaur: Approach to Anemia – More Than Just a Low Hemoglobin